Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychloro.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)

Other Treatments Global Adoption
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Libster (DB RCT) 50% 0.50 [0.09-2.65] death 2/80 4/80 Improvement, RR [CI] Treatment Control Balcells (RCT) -247% 3.47 [0.35-11.9] death 5/28 2/30 Korley (RCT) -396% 4.96 [0.58-42.2] death 5/250 1/248 Tau​2 = 0.74; I​2 = 47.5% Early treatment -93% 1.93 [0.47-7.87] 12/358 7/358 -93% improvement Gharbharan (RCT) 4% 0.96 [0.25-2.41] death 6/43 11/43 Improvement, RR [CI] Treatment Control Li (RCT) 35% 0.65 [0.27-1.39] death 8/51 12/50 Avendaño-Solà (RCT) 88% 0.12 [0.01-2.11] death 0/38 4/43 Agarwal (RCT) -7% 1.07 [0.73-1.58] death 34/235 31/229 Bajpai (RCT) -323% 4.23 [0.43-41.6] death 3/14 1/15 AlQahtani (RCT) 50% 0.50 [0.05-5.08] death 1/20 2/20 Simonovich (RCT) 4% 0.96 [0.50-1.83] death 25/228 12/105 Ray (RCT) 33% 0.67 [0.30-1.50] death 10/40 14/40 Recovery Co.. (RCT) 0% 1.00 [0.93-1.07] death 1,399/5,795 1,408/5,763 Bégin (RCT) -13% 1.13 [0.88-1.45] death 156/625 69/313 Tau​2 = 0.00; I​2 = 0.0% Late treatment -0% 1.00 [0.94-1.07] 1,642/7,089 1,564/6,621 -0% improvement All studies -1% 1.01 [0.90-1.13] 1,654/7,447 1,571/6,979 -1% improvement 13 convalescent plasma COVID-19 studies c19early.com/cp Dec 5, 2021 Tau​2 = 0.00; I​2 = 6.8%; Z = 0.18 Effect extraction pre-specified Favors conv. plasma Favors control
Database of all convalescent plasma COVID-19 studies. Submit updates/corrections.
 
Search:  
Restrict:    All    Early    Late
Sep 9
Late Bégin et al., Nature Medicine, doi:10.1038/s41591-021-01488-2 (Peer Reviewed)
death, ↑13.0%, p=0.33
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
Details   RCT 940 hospitalized patients, 614 assigned to convalescent plasma, showing no significant differences. NCT04348656.
Aug 18
Early Korley et al., NEJM, doi:10.1056/NEJMoa2103784 (Peer Reviewed)
death, ↑396.0%, p=0.22
Early Convalescent Plasma for High-Risk Outpatients with Covid-19
Details   RCT 511 emergency department patients, 257 assigned to convalescent plasma, showing no significant difference in outcomes.
Mar 3
Early Balcells et al., PLOS Medicine, doi:10.1371/journal.pmed.1003415 (Peer Reviewed)
death, ↑247.4%, p=0.17
Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial
Details   Small RCT with 28 early and 30 deferred (treated according to prespecified deterioration criteria) convalescent plasma patients, not showing significant differences. "Early" is relative, with a median of 5 days from symptom onse..
Jan 15
Late Recovery Collaborative Group, The Lancet, doi:10.1016/S0140-6736(21)00897-7 (press release 1/15/2021) (Peer Reviewed)
death, 0.0%, p=0.95
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Details   RCT 16,287 hospitalized patients in the UK, showing no significant differences with convalescent plasma treatment. Subgroup analysis shows better results for those treated <= 7 days from symptom onset. NCT04381936.
Jan 6
Early Libster et al., NEJM, doi:10.1056/NEJMoa2033700 (Peer Reviewed)
death, ↓50.0%, p=0.43
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
Details   RCT 160 patients >=65 with symptom onset <72 hours, 80 treated with convalescent plasma, showing lower progression to severe disease with treatment. NCT04479163.
Nov 29
2020
Late Ray et al., medRxiv, doi:10.1101/2020.11.25.20237883 (Peer Reviewed)
death, ↓33.0%, p=0.34
Clinical and immunological benefits of convalescent plasma therapy in severe COVID-19: insights from a single center open label randomised control trial
Details   Small RCT 80 hospitalized patients in India, 40 treated with convalescent plasma, not showing significant differences in primary analysis. Authors note that significant improvement in hypoxia, reduction in hospital stay, and survival bene..
Nov 24
2020
Late Simonovich et al., NEJM, doi:0.1056/NEJMoa2031304 (Peer Reviewed)
death, ↓4.1%, p=1.00
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
Details   RCT 333 hospitalized patients in Argentina, 228 treated with convalescent plasma, showing no significant differences in clinical status or mortality. NCT04383535.
Nov 4
2020
Late AlQahtani et al., Scientific Reports, doi:10.1038/s41598-021-89444-5 (preprint 11/4/2020) (Peer Reviewed)
death, ↓50.0%, p=0.55
Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease
Details   Small RCT with 40 hospitalized patients in Bahrain, 20 treated with convalescent plasma, not showing significant differences. NCT04356534.
Oct 27
2020
Late Bajpai et al., medRxiv, doi:10.1101/2020.10.25.20219337 (Preprint)
death, ↑323.0%, p=0.22
Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial
Details   Small RCT 29 patients in India, 14 treated with convalescent plasma, not showing significant differences with treatment.
Oct 22
2020
Late Agarwal et al., BMJ, doi:10.1136/bmj.m3939 (Peer Reviewed)
death, ↑7.0%, p=0.74
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Details   RCT 464 hospitalized patients in India, 235 treated with convalescent plasma, showing no improvement in combined death at 28 days or progression to severe disease. CTRI/2020/04/024775.
Sep 29
2020
Late Avendaño-Solà et al., medRxiv, doi:10.1101/2020.08.26.20182444 (Peer Reviewed)
death, ↓88.3%, p=0.12
Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial
Details   Early terminated RCT with 81 hospitalized patients, 38 treated with convalescent plasma, showing lower progression with treatment. NCT04345523.
Jun 3
2020
Late Li et al., JAMA, doi:10.1001/jama.2020.10044 (Peer Reviewed)
death, ↓34.6%, p=0.30
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial
Details   Small RCT 103 severe condition patients, 52 treated with convalescent plasma, showing improved viral clearance but no statistically significant improvements in mortality or clinical improvement. ChiCTR2000029757.
May 27
2020
Late Gharbharan et al., Nature Communications, doi:10.1038/s41467-021-23469-2 (Peer Reviewed)
death, ↓3.8%, p=0.95
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
Details   RCT 86 hospitalized patients, 43 treated with convalescent plasma, not showing significant differences with treatment. Authors conclude that the most likely explanation was already high antibody titers on the day of inclusion, and they re..
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit